Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-25T06:04:26.544Z Has data issue: false hasContentIssue false

Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230

Published online by Cambridge University Press:  01 November 1999

J. HEALER
Affiliation:
Institute of Cell, Animal and Population Biology, Division of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh EH 9 3JT, UK Present address: Walter and Eliza Hall Institute of Medical Research Melbourne, Australia.
D. McGUINNESS
Affiliation:
Institute of Cell, Animal and Population Biology, Division of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh EH 9 3JT, UK
R. CARTER
Affiliation:
Institute of Cell, Animal and Population Biology, Division of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh EH 9 3JT, UK
E. RILEY
Affiliation:
Institute of Cell, Animal and Population Biology, Division of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh EH 9 3JT, UK Present address: London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.

Abstract

Malaria-immune human sera were tested for their ability to affect the infectivity of Plasmodium falciparum gametocytes to Anopheles stephensi mosquitoes. Transmission-reducing effects of the sera were associated with the presence of antibodies to the gamete surface protein, Pfs230. Enhancement of transmission, manifest as elevated numbers of oocysts relative to controls, was observed for a number of sera, but was not found to be associated with antibodies against Pfs230. These results confirm that Pfs230 is a possible candidate for inclusion in a transmission-blocking malaria vaccine.

Type
Research Article
Copyright
1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)